Fraxiparin solution for injections syringe 0.6 ml. №10


Manufacturer: France

Treatment of thromboembolic complications.



Fraxiparin 0.6 ml Storage
Active substance: nadroparin calcium.

1 ml of solution contains 9500 IU of anti-Xa nadroparin calcium.

1 pre-filled syringe (0.6 ml) contains 5700 IU of anti-Xa nadroparin calcium.

Excipients: calcium hydroxide solution (or dilute hydrochloric acid), water for injections.

Fraxiparin 0.6 ml Release form
2 pre-filled glass syringes with automatic safety system in a blister; 5 blisters in a cardboard box. Solutions for injection in pre-filled syringes contain: volume, ml – Syringe – Nadroparin calcium, MO anti-XA 0.6 – Graduated – 5,700 0.8 – Graduated – 7,600

Dosage form
Solution for injection.

Main physical and chemical properties: clear or slightly opalescent, colorless or light yellow solution.

Active substance

Nadroparin is a low molecular weight heparin developed by depolymerization of standard heparin. Is a glycosaminoglycan with an average molecular weight of 4300 daltons. Nadroparin shows a high level of binding to plasma protein antithrombin III. This relationship leads to accelerated inhibition of factor Xa, which is a major contributor to the high antithrombotic activity of nadroparin. Other mechanisms of nadroparin antithrombotic activity are stimulation of tissue factor pathway inhibitor, activation of fibrinolysis by direct release of tissue plasminogen activator from endothelial cells, modification of hemorheological parameters (decrease in blood viscosity and increase in platelet and membrane membranes). Nadroparin has a high ratio between anti-Xa and anti-IIa activity. It has an immediate and prolonged antithrombotic effect. Compared to unfractionated heparin, nadroparin has less effect on platelet function and aggregation and has very little effect on primary hemostasis.

Fraxiparin 0.6 ml Pharmacokinetics
Pharmacokinetic properties are determined by measuring the anti-Xa factor activity of blood plasma.

Prevention of thromboembolic complications

– as a result of general or orthopedic surgical interventions;

– in patients at high risk of thromboembolic complications (respiratory failure and / or infectious diseases of the respiratory tract, and / or heart failure), hospitalized in the intensive care unit.

Treatment of thromboembolic complications.

Prevention of blood clotting during hemodialysis.

Treatment of unstable angina and myocardial infarction without pathological Q wave on the ECG.